Accurate determination of the predictive markers human epidermal growth factor receptor 2 (HER2/ERBB2), estrogen receptor (ER/ESR1), progesterone receptor (PgR/PGR), and marker of proliferation Ki67 (MKI67) is indispensable for therapeutic decision making in early breast cancer. In this multicenter prospective study, we addressed the issue of inter- and intrasite reproducibility using the recently developed reverse transcription-quantitative real-time polymerase chain reaction-based MammaTyper® test.
An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper® / Z. Varga, A. Lebeau, H. Bu, A. Hartmann, F. Penault Llorca, E. GUERINI ROCCO, P. Schraml, F. Symmans, R. Stoehr, X. Teng, A. Turzynski, R. von Wasielewski, C. Gürtler, M. Laible, K. Schlombs, H. Joensuu, T. Keller, P. Sinn, U. Sahin, J. Bartlett, G. Viale. - In: BREAST CANCER RESEARCH. - ISSN 1465-542X. - 19:1(2017 May 11). [10.1186/s13058-017-0848-z]
An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®
E. GUERINI ROCCO;G. VialeUltimo
2017
Abstract
Accurate determination of the predictive markers human epidermal growth factor receptor 2 (HER2/ERBB2), estrogen receptor (ER/ESR1), progesterone receptor (PgR/PGR), and marker of proliferation Ki67 (MKI67) is indispensable for therapeutic decision making in early breast cancer. In this multicenter prospective study, we addressed the issue of inter- and intrasite reproducibility using the recently developed reverse transcription-quantitative real-time polymerase chain reaction-based MammaTyper® test.
| File | Dimensione | Formato | |
|---|---|---|---|
|
mammatyper.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.25 MB
Formato
Adobe PDF
|
1.25 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
